Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-02-24
    E.g., 2018-02-24

Articles

171624 items
7:24 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Proposed Offerings

Addex proposes CHF40M private placement

Neurology company Addex Therapeutics Ltd. (SIX:ADXN) proposed on Feb. 15 to raise up to CHF40 million ($42.7 million) through the sale of 12.8 million shares at CHF3.43 in a private placement. The company said CHF30...
7:24 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Kallyope raises $66M in series B

Kallyope Inc. (New York, N.Y.) raised $66 million on Feb. 22 in a series B round. Existing investors Lux Capital, The Column Group, Polaris Partners, Illumina Ventures and Alexandria Venture Investments participated, as did new...
7:23 AM, Feb 23, 2018  |  BC Week In Review | Financial News  |  Completed Offerings

Oric raises $50M series C

Cancer company Oric Pharmaceuticals Inc. (South San Francisco, Calif.) said on Feb. 21 it raised $50 million in a series C round from new investors Fidelity Management & Research, Trinitas Capital, Taiho Ventures and NS...
7:23 AM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Merck buying oncolytic virus play Viralytics for $398M

Merck & Co. Inc. (NYSE:MRK) will acquire oncolytic immunotherapy company Viralytics Ltd. (ASX:VLA; OTCQX:VRACY) for A$1.75 per share, or A$502 million ($398 million). The price is a 182% premium to Viralytics’ close of A$0.62 on...
7:23 AM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Takeda, Wave in CNS nucleic acid deal

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) and Wave Life Sciences Ltd. (NASDAQ:WVE) partnered to develop and commercialize nucleic acid therapies to treat CNS diseases. Wave will receive an upfront payment of $170 million, including $110 million in...
7:22 AM, Feb 23, 2018  |  BC Week In Review | Company News  |  Deals

Ionis, AstraZeneca in antisense kidney disease deal

Ionis Pharmaceuticals Inc. (NASDAQ:IONS) granted AstraZeneca plc (LSE:AZN; NYSE:AZN) worldwide rights to develop and commercialize antisense candidate IONIS-AZ5-2.5Rx (AZD2373), which is in development to treat an undisclosed genetically associated form of kidney disease. Ionis will...
7:22 AM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Preclinical Results

Visterra reports preclinical data for dengue fever candidate

Visterra Inc. (Cambridge, Mass.) reported preclinical data from mouse models of primary and secondary dengue fever infection showing that VIS513 significantly reduced viral titers vs. controls and protected mice from lethal infections. Data were published...
7:22 AM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novo's oral GLP-1 analog meets in first Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said oral semaglutide met the primary endpoint in the Phase IIIa PIONEER 1 trial to treat Type II diabetes. The candidate is on track to be the first approved oral...
7:21 AM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Ionis' Akcea reports Phase I/IIa data for AKCEA-APOCIII-LRx in hypertriglyceridemia

In October, Akcea Therapeutics Inc. (NASDAQ:AKCA) reported data from a Phase I/IIa trial in about 56 healthy volunteers and patients with hypertriglyceridemia showing that AKCEA-APOCIII-LRx (IONIS-APOCIII-LRx) led to reductions in apolipoprotein C-III (APOCIII; APOC3) protein...
7:21 AM, Feb 23, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Provectus reports Phase Ib data for PV-10 in melanoma

In October, Provectus Biopharmaceuticals Inc. (OTCQB:PVCT) reported preliminary data from 10 evaluable patients with stage IV metastatic melanoma in the Phase Ib portion of a Phase Ib/II trial showing that PV-10 (Provecta) plus Keytruda pembrolizumab...

Pages